The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s showing significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to offer a greater substantial decrease in body weight and enhance metabolic health, part